Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1).
This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States.
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases have overcome technical obstacles to produce a homogeneous, soluble RSV F glycoprotein vaccine which is stabilized in the prefusion conformation and has improved stability and immunogenicity compared to the native protein. Additionally, several modifications were introduced to remove the requirement for furin during production, resulting in an increase in expression levels of the immunogen.
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases designed fusion peptide immunogens that were comprised of the exposed residues of the fusion peptide coupled to highly immunogenic carrier proteins to focus the immune response. The fusion peptide can be displayed on scaffold proteins and – when coupled to HIV-1 Env trimer boosts – has the potential to elicit antibodies capable of neutralizing diverse HIV-1 strains in mice, guinea pigs and rhesus macaques, and might therefore serve as the basis for an effective HIV vaccine.
Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice.
Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.
NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future.
The Cuban Center for Neurosciences (CNEURO), a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, has developed a portfolio of technologies and services to diagnose and treat brain disorders and promote mental health from infancy to old age.
A novel, disease-modifying Alzheimer’s disease therapeutic, designed by KalGene Pharmaceuticals, could be the breakthrough sought by both patients and clinicians.
Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.
Biotech company Actinogen Medical is developing Xanamem, a drug designed to inhibit the increased production of cortisol in the brain, which has been linked to cognitive decline and Alzheimer’s disease.
With multiple products in advanced clinical stages, including oral calcitonin gene-related peptide receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors, Biohaven is advancing collaborations on these programs and broadening its pipeline.
The Antibody Lab’s proprietary cell line development technology enables drug developers to move seamlessly from preclinical discovery to manufacture of the biologic for clinical testing. BESTcell clonal Chinese hamster ovary cell lines can be rapidly generated to enable preclinical testing of multiple biologic drug candidates. After selection of the final candidate, the respective cell line can be used to manufacture master cell banks. This revolutionary approach shortens timelines and reduces the reproducibility risk associated with changing the source of the biologic during research and development.
NBE-Therapeutics is developing a novel class of immune-stimulatory antibody drug conjugates (iADCs) that not only target and destroy cancer cells, but also trigger long-lasting antitumor immunity.
YUMAB, a global provider of fully human monoclonal antibody discovery and development, delivers the antibodies closest to germline on the market. The company provides crucial support to innovators such as Singapore-based startup Enleofen Bio, an exciting new player in fibrosis.
Cold Genesys is developing CG0070, a promising oncolytic virus that is proving successful in trials as a single agent, with near-term plans to develop it in combination with immuno-oncology agents.
Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.
